Genmab — Januar 2013
-
-
Among the newest drugs the myeloma specialists mentioned as particularly promising, daratumumab was the only one mentioned by almost all of the myeloma specialists The Beacon consulted about the ASH meeting.
“In my view, daratumumab had the most impressive data with activity in the majority of very heavily pretreated patients,” said Dr. Reu. “Many feel this could become
the ‘rituximab [Rituxan] for myeloma,’’’ he further explained -
Det sender genmab pænt over 500 hvis det en realitet
-
Men det varer en del år før det kan folde sig ud
-
Synes lidt igen det blev antydet på Post-ASH seminaret af Paul Richardson, at man hvis data er gode måske kan søge om accelerated approval på baggrund af nuværende fase I/II studie - andre der hørte det lidt på samme måde ?? Man har jo også ændret protokollen, så flere patienter rulles ind og behandles i længere tid, så vidt jeg lige hørte det !
-
men ville han ikke svarer på det direkte, hvis det var sandt, eller er det en Janssen beslutning?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind